Revolution Medicines Picks Up $25M For Cancer Efforts
Redwood City-based Revolution Medicines, a biopharmaceuticals firm aiming to treat cancer by attacking frontier oncology targets, proteins which drive the growth of cancer, has raised $25M in a Series A extension financing. The funding came from The Column Group, in addition to earlier funding from Third Rock Ventures. Column Group partner Larry Lasky joins the company's board with the funding. Mark A. Goldsmith is President and CEO of Revolution Medicines.
posted on Wednesday, December 21, 2016 (Link to more information)
Related companies:
REVOLUTION ANALYTICS, INC.
Related stories:
> Ambys Medicines Snags $140M
> Revolution Foods Harvests $30M For Fresh Meals
> Billing Revolution Scores Strategic Investment
> Igenica Raises $33M For Cancer Antibodies
> Revolution Analytics Acquired By Microsoft
silicontap.com Home